BiotechTube

VX-522 mRNA therapy + IVA

Phase 1/2Recruiting
0 watching 0 views this week💤 Quiet
38
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cystic Fibrosis

Conditions

Cystic Fibrosis

Trial Timeline

Feb 27, 2023 → May 12, 2027

NCT ID
NCT05668741

About VX-522 mRNA therapy + IVA

VX-522 mRNA therapy + IVA is a phase 1/2 stage product being developed by Moderna for Cystic Fibrosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05668741. Target conditions include Cystic Fibrosis.

Hype Score Breakdown

Clinical
13
Activity
8
Company
7
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT05668741Phase 1/2Recruiting

Competing Products

20 competing products in Cystic Fibrosis

See all competitors
ProductCompanyStageHype Score
Tildacerfont + PlaceboSpruce BiosciencesPhase 2
44
Enfortumab VedotinAstellas PharmaPhase 2
52
CefiderocolShionogiApproved
85
LenvatinibEisaiPhase 2
52
Lenvatinib + PembrolizumabEisaiPhase 2
52
CREONAbbVieApproved
85
Pancrelipase + PancrelipaseAbbVieApproved
85
Creon IR + Creon® (DR/GR)AbbViePhase 2
52
ABBV-CLS-628 + PlaceboAbbViePhase 2
52
Elagolix + PlaceboAbbViePhase 2
52
ABBV-3067 + Placebo ABBV-3067 + ABBV-2222 + Placebo ABBV-2222AbbViePhase 2
52
ABBV-576 + Galicaftor + Placebo + Navocaftor + ABBV-119AbbViePhase 2
52
Benralizumab + Placebo to BenralizumabAstraZenecaPhase 3
77
AZD5634 for inhalation + AZD5634 for infusionAstraZenecaPhase 1
33
Metformin XR + Saxagliptin + Saxagliptin-Metformin XRAstraZenecaPhase 3
77
AZD1236 + PlaceboAstraZenecaPhase 2
52
Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ERAstraZenecaPhase 3
77
AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part BAstraZenecaPhase 1
33
AZD9668 + AZD9668 Placebo equivalentAstraZenecaPhase 2
52
AZD4901 (oral) + Placebo to match AZD4901AstraZenecaPhase 2
52